You are viewing just a glimpse of the 100+ pieces of sophisticated insight and analysis produced by our full-time team of senior financial journalists every day. For full access, check to see if your firm has a license to The Deal Pipeline or login using your existing credentials.
Published July 21, 2009 at 1:50 PM
Legislative patent reform may be stalled, but U.S. courts have decided, or are considering, a number of precedent-setting intellectual property cases. One of the most recent was the Supreme Court's ruling that pharmaceutical drugmaker MedImmune Inc. could challenge the validity of a Genentech Inc. patent without first breaching a licensing agreement it had with Genentech. (The Deal Pipeline subscribers can get the details here.)
This fall, the Supreme Court is expecting to take up another important IP case, Bilski v. Doll, which centers on the ability to patent a method of hedging risks in commodities trading. In this edition of Inside The Deal, Jeff Whittle, a partner with Bracewell and Giuliani LLP, says one question the court will consider is how difficult enforcement of a business method patent would be. - Suzanne Stevens
Leezie Kim is rejoining the Phoenix office of Quarles & Brady LLP as a partner. She will continue her corporate transactions practice. For other updates launch today's Movers & shakers slideshow.
Dechert's Henry Nassau at the 18th annual Wharton Private Equity and Venture Capital Conference tells The Deal Pipeline how to shine in the middle market. More video
Search
